Welcome to Arctom, sign up to enjoy up to 20% OFF

Search in Small Molecules Search in Biologics

Structure Search

Cart - 0 item(s)
$0.00

Your shopping cart is empty!

Chemistry
Inhibitors
- Anti-infection
Natural Products
ADCs
Antibodies
Multiplex IHC
Material Science
Others

[CAS NO. 149647-78-9] Vorinostat

Ships within

Stock

Price

Qty

Total

SDS

COA

Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.

Catalog:	HY-10221
Brand:	MCE
CAS:	149647-78-9

Overview

MDL	MFCD00945317
Molecular Weight	264.32
Molecular Formula	C14H20N2O3
SMILES	O=C(NC1=CC=CC=C1)CCCCCCC(NO)=O

For research use only. We do not sell to patients.

72 Publications Citing Use of MCE

[1]Mol Psychiatry. 2017 May;22(5):711-723.
[2]Nat Commun. 2021 Mar 3;12(1):1407.
[3]Nat Commun. 2017 Dec 20;8(1):2207.
[4]J Exp Med. 2022 Jan 3;219(1):e20210789.
[5]Cell Syst. 2019 Jul 24;9(1):35-48.e5.
[6]Cell Rep. 2023 Jan 31.
[7]Oncogene. 2021 Apr;40(15):2711-2724.
[8]Br J Pharmacol. 2021 Sep;178(17):3428-3447.
[9]Acta Pharm Sin B. 21 July 2021.
[10]Cell Death Dis. 2023 Jan 18;14(1):38.
[11]Cell Death Dis. 2023 Jan 25;14(1):59.
[12]Cell Death Dis. 2022 Aug 17;13(8):717.
[13]Cell Death Dis. 2021 Jun 7;12(6):582.
[14]Cell Death Dis. 2020 Sep 18;11(9):778.
[15]Cell Death Dis. 2020 Sep 15;11(9):753.
[16]JCI Insight. 2021 Dec 7;e153948.
[17]Stem Cell Reports. 2017 Dec 12;9(6):1948-1960.
[18]J Clin Endocrinol Metab. 2021 Jan 1;106(1):e232-e246.
[19]Am J Cancer Res. 2022 Feb 15;12(2):713-728.
[20]Acta Pharmacol Sin. 2021 Apr 13.
[21]Acta Pharmacol Sin. 2020 Aug 27.
[22]Acta Pharmacol Sin. 2019 Jan;40(1):98-110.
[23]Immunology. 2020 Jun;160(2):183-197.
[24]Biochem Pharmacol. 2022 May 5;201:115070.
[25]Biochem Pharmacol. 2021 Dec 28;114901.
[26]Biochem Pharmacol. 2019 Jun;164:237-251.
[27]Biochem Pharmacol. 2018 Oct;156:511-523.
[28]Antimicrob Agents Chemother. 2021 Sep 7;AAC0047021.
[29]Front Oncol. 2021 Apr 22;11:665763.
[30]Front Oncol. 2021 Mar 8;11:620154.
[31]Front Oncol. 2021; 11: 620154.
[32]Aging. 2021 May 28;13(11):15336-15352.
[33]J Virol. 2021 Jul 21;JVI0022721.
[34]Biochim Biophys Acta Gene Regul Mech. 2018 May 18;S1874-9399(18)30028-2.
[35]Nanomaterials. 2020 Jan 16;10(1):158.
[36]Hum Gene Ther. 2019 Apr;30(4):497-510.
[37]Commun Biol. 2021 Oct 29;4(1):1235.
[38]Front Cell Infect Microbiol. 19 July 2021.
[39]J Proteome Res. 2022 Feb 16.
[40]Sci Rep. 2022 Jun 15;12(1):9951.
[41]Int J Oncol. 2020 Jun;56(6):1429-1441.
[42]Life Sci. 2021 Feb 15;267:118427.
[43]Hum Cell. 2020 Oct;33(4):1006-1016.
[44]J Taibah Univ Med Sci. 21 July 2022.
[45]Exp Cell Res. 2020 Aug 1;393(1):112054.
[46]Onco Targets Ther. 2018 Apr 17;11:2177-2184.
[47]Molecules. 2018 Mar 23;23(4). pii: E736.
[48]Eur J Pharmacol. 2021 Jul 29;908:174399.
[49]Drug Des Devel Ther. 2018 Apr 30;12:1009-1017.
[50]Neurocrit Care. 2022 Jun 1.
[51]BMC Cancer. 2023 Jan 25;23(1):87.
[52]RSC Adv., 2018, 8, 17279-17292
[53]Vet Microbiol. 2019 Nov;238:108436.
[54]Eur Rev Med Pharmacol Sci. 2020; 24 (10): 5726-5733
[55]Pharm Biol. 2021 Dec;59(1):21-30.
[56]J Sep Sci. 2022 Nov 25.
[57]Virology. 11 October 2022.
[58]Biol Pharm Bull. 2017;40(10):1747-1753.
[59]Mil Med Res. 2022 Sep 27;9(1):54.
[60]Research Square Print. September 20th, 2022.
[61]Pharmaceuticals. 2022, 15(3), 338.
[62]Research Square Preprint. 2022 Feb.
[63]Università degli Studi di CAGLIARI. Dipartimento di Scienze Biomediche. 2021 May.
[64]Research Square Preprint. 2021 May.
[65]bioRxiv. 2021 Jan 5.
[66]The Faculty For Chemie And Pharmazie, Albert-ludwigs-university Of Freiburg. 2019 Dec.
[67]Biochemistry and Molecular Biology. Florida Southern College. 2019 May.
[68]Patent. US20180263995A1.
[69]Oncotarget. 2017 Dec 2;8(68):112313-112329.
[70]Oncotarget. 2017 May 23;8(21):34362-34373.
[71]Universidad Autónoma de Madrid, Facultad de Ciencias, Departamento de Biología Molecular. 15-06-2015.
[72]Harvard Medical School LINCS LIBRARY

Summary

Vorinostat (SAHA) is a potent and orally active pan-inhibitor of HDAC1 , HDAC2 and HDAC3 (Class I) , HDAC6 and HDAC7 (Class II) and HDAC11 (Class IV) , with ID ₅₀ values of 10 nM and 20 nM for HDAC1 and HDAC3 , respectively. Vorinostat induces cell apoptosis ^[1] ^[4] . Vorinostat is also an effective inhibitor of human papillomaviruse (HPV)-18 DNA amplification ^[7] .

IC50 & Target

HDAC1

10 nM (ID ₅₀ )

HDAC3

20 nM (ID ₅₀ )

HDAC2

HDAC7

HDAC11

Autophagy

Mitophagy

In Vitro

Vorinostat efficiently suppresses MES-SA cell growth at a low dosage (3 μM) already after 24 hours treatment. HDACs class I (HDAC2 and 3) as well as class II (HDAC7) are preferentially affected by this treatment. Vorinostat significantly increases p21 ^WAF1 expression and apoptosis in MES-SA cells ^[1] .
Vorinostat inhibits SK-N-SH and SK-N-Be(2)C with the IC ₂₅ values of 1 µM and 0.5 µM, respectively ^[2] .
Vorinostat is an effective inhibitor of HPV-18 DNA amplification, reduces oncoproteins E6 and E7 activities and triggers apoptosis in HPV-infected, differentiated cells ^[7] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Vorinostat (50 mg/kg/day) reduces tumor growth by more than 50% in nude mice injected with 5×10 ⁶ MES-SA cells ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT00762255	H. Lee Moffitt Cancer Center and Research Institute\|Merck Sharp & Dohme LLC	Glioblastoma	September 2008	Phase 1
NCT02124083	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)\|Washington University School of Medicine\|Weill Medical College of Cornell University\|National Institutes of Health Clinical Center (CC)	Neimann-Pick Disease	April 25, 2014	Phase 1\|Phase 2
NCT01019850	New Approaches to Neuroblastoma Therapy Consortium\|National Cancer Institute (NCI)	Neuroblastoma	March 2010	Phase 1
NCT00357305	National Cancer Institute (NCI)	Accelerated Phase Chronic Myelogenous Leukemia\|Adult Acute Basophilic Leukemia\|Adult Acute Eosinophilic Leukemia\|Adult Acute Megakaryoblastic Leukemia (M7)\|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)\|Adult Acute Monoblastic Leukemia (M5a)\|Adult Acute Monocytic Leukemia (M5b)\|Adult Acute Myeloblastic Leukemia With Maturation (M2)\|Adult Acute Myeloblastic Leukemia Without Maturation (M1)\|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities\|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)\|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)\|Adult Acute Myelomonocytic Leukemia (M4)\|Adult Acute Promyelocytic Leukemia (M3)\|Adult Erythroleukemia (M6a)\|Adult Pure Erythroid Leukemia (M6b)\|Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative\|Blastic Phase Chronic Myelogenous Leukemia\|Chronic Eosinophilic Leukemia\|Chronic Myelomonocytic Leukemia\|Chronic Neutrophilic Leukemia\|de Novo Myelodysplastic Syndromes\|Essential Thrombocythemia\|Myelodysplastic+Myeloproliferative Neoplasm, Unclassifiable\|Polycythemia Vera\|Previously Treated Myelodysplastic Syndromes\|Primary Myelofibrosis\|Recurrent Adult Acute Lymphoblastic Leukemia\|Recurrent Adult Acute Myeloid Leukemia\|Relapsing Chronic Myelogenous Leukemia\|Secondary Acute Myeloid Leukemia\|Secondary Myelodysplastic Syndromes	May 2006	Phase 1
NCT02638090	H. Lee Moffitt Cancer Center and Research Institute\|Merck Sharp & Dohme LLC	Lung Cancer\|Non-small Cell Lung Cancer	March 22, 2016	Phase 1\|Phase 2
NCT00331513	National Cancer Institute (NCI)	Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome\|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities\|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)\|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)\|Adult Acute Promyelocytic Leukemia (M3)\|Blastic Phase Chronic Myelogenous Leukemia\|Myelodysplastic+Myeloproliferative Neoplasm, Unclassifiable\|Previously Treated Myelodysplastic Syndromes\|Recurrent Adult Acute Lymphoblastic Leukemia\|Recurrent Adult Acute Myeloid Leukemia\|Relapsing Chronic Myelogenous Leukemia\|Secondary Acute Myeloid Leukemia\|Secondary Myelodysplastic Syndromes	March 2006	Phase 1
NCT00128102	Merck Sharp & Dohme LLC	Mesothelioma\|Lung Cancer	June 30, 2005	Phase 3
NCT03382834	National Institute of Allergy and Infectious Diseases (NIAID)	HIV Infections	April 26, 2018	Phase 2
NCT02589145	M.D. Anderson Cancer Center\|Celgene Corporation	Lymphoma	June 22, 2016	Phase 1\|Phase 2
NCT00287937	National Cancer Institute (NCI)	Unspecified Adult Solid Tumor, Protocol Specific	July 2005	Phase 1
NCT03713320	miRagen Therapeutics, Inc.	Cutaneous T-Cell Lymphoma+Mycosis Fungoides	April 2, 2019	Phase 2
NCT00764517	OHSU Knight Cancer Institute\|National Cancer Institute (NCI)	Recurrent B-Cell Non-Hodgkin Lymphoma\|Recurrent Chronic Lymphocytic Leukemia\|Recurrent Indolent Adult Non-Hodgkin Lymphoma\|Refractory B-Cell Non-Hodgkin Lymphoma	August 2008	Phase 2
NCT01120834	Weill Medical College of Cornell University\|Celgene\|Merck Sharp & Dohme LLC	Lymphoma	September 2010	Phase 1\|Phase 2
NCT02412475	Michael Burke\|Children´s Hospitals and Clinics of Minnesota\|Medical College of Wisconsin	Leukemia, Acute Myeloid	February 21, 2015	Phase 1
NCT01194427	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|Merck Sharp & Dohme LLC	Stage I Breast Cancer\|Stage II Breast Cancer\|Stage III Breast Cancer\|Invasive Breast Cancer	March 2011	Phase 2
NCT00305773	National Cancer Institute (NCI)	Adult Acute Erythroid Leukemia (M6)\|Adult Acute Megakaryoblastic Leukemia (M7)\|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)\|Adult Acute Monoblastic Leukemia (M5a)\|Adult Acute Monocytic Leukemia (M5b)\|Adult Acute Myeloblastic Leukemia With Maturation (M2)\|Adult Acute Myeloblastic Leukemia Without Maturation (M1)\|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities\|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)\|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)\|Adult Acute Myelomonocytic Leukemia (M4)\|Adult Acute Promyelocytic Leukemia (M3)\|Recurrent Adult Acute Myeloid Leukemia\|Refractory Cytopenia With Multilineage Dysplasia\|Secondary Acute Myeloid Leukemia\|Untreated Adult Acute Myeloid Leukemia	January 2006	Phase 2
NCT00555399	M.D. Anderson Cancer Center\|Merck Sharp & Dohme LLC	Glioblastoma Multiforme\|Anaplastic Glioma	November 28, 2007	Phase 1\|Phase 2
NCT01267240	National Cancer Institute (NCI)	Paranasal Sinus Squamous Cell Carcinoma\|Recurrent Hypopharyngeal Squamous Cell Carcinoma\|Recurrent Laryngeal Squamous Cell Carcinoma\|Recurrent Oral Cavity Squamous Cell Carcinoma\|Recurrent Oropharyngeal Squamous Cell Carcinoma\|Stage IVA Hypopharyngeal Squamous Cell Carcinoma\|Stage IVA Laryngeal Squamous Cell Carcinoma\|Stage IVA Oral Cavity Squamous Cell Carcinoma\|Stage IVA Oropharyngeal Squamous Cell Carcinoma\|Stage IVB Hypopharyngeal Squamous Cell Carcinoma\|Stage IVB Laryngeal Squamous Cell Carcinoma\|Stage IVB Oral Cavity Squamous Cell Carcinoma\|Stage IVB Oropharyngeal Squamous Cell Carcinoma\|Stage IVC Hypopharyngeal Squamous Cell Carcinoma\|Stage IVC Laryngeal Squamous Cell Carcinoma\|Stage IVC Oral Cavity Squamous Cell Carcinoma\|Stage IVC Oropharyngeal Squamous Cell Carcinoma	December 2010	Phase 2
NCT01064921	Ohio State University Comprehensive Cancer Center\|National Comprehensive Cancer Network	Stage III Squamous Cell Carcinoma of the Oropharynx\|Stage IV Squamous Cell Carcinoma of the Oropharynx	January 19, 2010	Phase 1
NCT00126451	Merck Sharp & Dohme LLC	Breast Cancer\|Colorectal Cancer\|Non-small-cell Lung Carcinoma	December 1, 2004	Phase 2
NCT00121277	University Health Network, Toronto\|National Cancer Institute (NCI)	Unspecified Adult Solid Tumor, Protocol Specific	September 2005	Phase 1
NCT00253630	National Cancer Institute (NCI)	Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue\|Nodal Marginal Zone Lymphoma\|Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Grade 3 Follicular Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Marginal Zone Lymphoma	September 2005	Phase 2
NCT00331955	National Cancer Institute (NCI)	Unspecified Adult Solid Tumor, Protocol Specific	March 2006	Phase 1
NCT03878524	OHSU Knight Cancer Institute\|Oregon Health and Science University	Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive\|Anatomic Stage IV Breast Cancer AJCC v8\|Anemia\|Ann Arbor Stage III Hodgkin Lymphoma\|Ann Arbor Stage III Non-Hodgkin Lymphoma\|Ann Arbor Stage IV Hodgkin Lymphoma\|Ann Arbor Stage IV Non-Hodgkin Lymphoma\|Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative\|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive\|Castration-Resistant Prostate Carcinoma\|Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive\|Hematopoietic and Lymphoid System Neoplasm\|Locally Advanced Pancreatic Adenocarcinoma\|Metastatic Breast Carcinoma\|Metastatic Malignant Solid Neoplasm\|Metastatic Pancreatic Adenocarcinoma\|Myelodysplastic+Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis\|Myelodysplastic+Myeloproliferative Neoplasm, Unclassifiable\|Primary Myelofibrosis\|Recurrent Acute Lymphoblastic Leukemia\|Recurrent Acute Myeloid Leukemia\|Recurrent Chronic Lymphocytic Leukemia\|Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive\|Recurrent Hematologic Malignancy\|Recurrent Hodgkin Lymphoma\|Recurrent Myelodysplastic Syndrome\|Recurrent Myelodysplastic+Myeloproliferative Neoplasm\|Recurrent Myeloproliferative Neoplasm\|Recurrent Non-Hodgkin Lymphoma\|Recurrent Plasma Cell Myeloma\|Recurrent Small Lymphocytic Lymphoma\|Refractory Acute Lymphoblastic Leukemia\|Refractory Acute Myeloid Leukemia\|Refractory Chronic Lymphocytic Leukemia\|Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive\|Refractory Chronic Myelomonocytic Leukemia\|Refractory Hematologic Malignancy\|Refractory Hodgkin Lymphoma\|Refractory Malignant Solid Neoplasm\|Refractory Myelodysplastic Syndrome\|Refractory Myelodysplastic+Myeloproliferative Neoplasm\|Refractory Non-Hodgkin Lymphoma\|Refractory Plasma Cell Myeloma\|Refractory Primary Myelofibrosis\|Refractory Small Lymphocytic Lymphoma\|Stage II Pancreatic Cancer AJCC v8\|Stage III Pancreatic Cancer AJCC v8\|Stage IV Pancreatic Cancer AJCC v8\|Stage IV Prostate Cancer AJCC v8\|Unresectable Pancreatic Adenocarcinoma	April 1, 2020	Phase 1
NCT00268385	National Cancer Institute (NCI)	Adult Anaplastic Astrocytoma\|Adult Anaplastic Oligodendroglioma\|Adult Giant Cell Glioblastoma\|Adult Glioblastoma\|Adult Gliosarcoma\|Adult Mixed Glioma\|Recurrent Adult Brain Neoplasm	December 16, 2005	Phase 1
NCT00907738	Merck Sharp & Dohme LLC	Advanced Cancer	August 2005	Phase 2
NCT00918723	Fred Hutchinson Cancer Center\|National Cancer Institute (NCI)	Chronic Lymphocytic Leukemia\|Stage I Chronic Lymphocytic Leukemia\|Stage I Small Lymphocytic Lymphoma\|Stage II Chronic Lymphocytic Leukemia\|Stage II Small Lymphocytic Lymphoma\|Stage III Chronic Lymphocytic Leukemia\|Stage III Small Lymphocytic Lymphoma\|Stage IV Chronic Lymphocytic Leukemia\|Stage IV Small Lymphocytic Lymphoma	June 2009	Phase 1\|Phase 2
NCT03259503	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Recurrent Diffuse Large B-Cell Lymphoma\|Recurrent T-Cell Non-Hodgkin Lymphoma\|Refractory Diffuse Large B-Cell Lymphoma\|Refractory Hodgkin Lymphoma\|Refractory T-Cell Non-Hodgkin Lymphoma	September 13, 2019	Phase 1
NCT02538510	University of Washington\|National Cancer Institute (NCI)	Head and Neck Squamous Cell Carcinoma\|Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma\|Recurrent Nasopharynx Carcinoma\|Recurrent Salivary Gland Carcinoma\|Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary\|Stage III Major Salivary Gland Carcinoma\|Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma\|Stage III Nasopharyngeal Carcinoma\|Stage IV Nasopharyngeal Carcinoma\|Stage IVA Major Salivary Gland Carcinoma\|Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma\|Stage IVB Major Salivary Gland Carcinoma\|Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma\|Stage IVC Major Salivary Gland Carcinoma\|Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma	October 8, 2015	Phase 1\|Phase 2
NCT00616967	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|National Cancer Institute (NCI)	Breast Cancer	May 2008	Phase 2
NCT00419367	Merck Sharp & Dohme LLC	Lymphoma, T-Cell, Cutaneous
NCT01838187	Children´s Hospital Medical Center, Cincinnati	Neuroblastoma\|Pheochromocytoma\|Paraganglioma
NCT00867178	National Cancer Institute (NCI)	Medulloblastoma\|Pineoblastoma\|Supratentorial Embryonal Tumor, Not Otherwise Specified	February 25, 2009	Phase 1
NCT00357708	National Cancer Institute (NCI)	Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities\|Adult Acute Myeloid Leukemia With Del(5q)\|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)\|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)\|Chronic Myelomonocytic Leukemia\|Myelodysplastic+Myeloproliferative Neoplasm, Unclassifiable\|Philadelphia Chromosome Negative Chronic Myelogenous Leukemia\|Previously Treated Myelodysplastic Syndromes\|Recurrent Adult Acute Lymphoblastic Leukemia\|Recurrent Adult Acute Myeloid Leukemia\|Relapsing Chronic Myelogenous Leukemia	June 2006	Phase 1
NCT00839956	Fred Hutchinson Cancer Center\|National Cancer Institute (NCI)	DS Stage I Plasma Cell Myeloma\|DS Stage II Plasma Cell Myeloma\|DS Stage III Plasma Cell Myeloma	February 2009	Phase 2
NCT03150329	City of Hope Medical Center\|National Cancer Institute (NCI)	Grade 3b Follicular Lymphoma\|Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma\|Recurrent Classic Hodgkin Lymphoma\|Recurrent Diffuse Large B-Cell Lymphoma\|Recurrent Follicular Lymphoma\|Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Grade 3a Follicular Lymphoma\|Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma\|Recurrent Transformed Non-Hodgkin Lymphoma\|Refractory B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma\|Refractory Classic Hodgkin Lymphoma\|Refractory Diffuse Large B-Cell Lymphoma\|Refractory Follicular Lymphoma\|Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma\|Refractory Transformed Non-Hodgkin Lymphoma	July 18, 2017	Phase 1
NCT01208454	National Cancer Institute (NCI)	Localized Unresectable Neuroblastoma\|Recurrent Neuroblastoma\|Regional Neuroblastoma\|Stage 4 Neuroblastoma\|Stage 4S Neuroblastoma	December 2010	Phase 1
NCT02042989	M.D. Anderson Cancer Center\|Millennium Pharmaceuticals, Inc.	Advanced Cancers	June 27, 2014	Phase 1
NCT00330161	National Cancer Institute (NCI)	Recurrent Prostate Cancer\|Stage IV Prostate Cancer	March 2006	Phase 2
NCT00818649	Masonic Cancer Center, University of Minnesota\|Merck Sharp & Dohme LLC\|Millennium Pharmaceuticals, Inc.	Leukemia\|Myelodysplastic Syndrome	January 2009	Phase 2
NCT01084057	City of Hope Medical Center	Male Breast Cancer\|Recurrent Breast Cancer\|Stage IV Breast Cancer	May 17, 2010	Phase 1
NCT01023737	Sukeshi Patel\|Merck Sharp & Dohme LLC\|The University of Texas Health Science Center at San Antonio	Malignant Solid Tumour	November 2009	Phase 1
NCT00324740	National Cancer Institute (NCI)	Recurrent Renal Cell Cancer\|Stage III Renal Cell Cancer\|Stage IV Renal Cell Cancer	March 2006	Phase 1\|Phase 2
NCT03167437	National Institute of Allergy and Infectious Diseases (NIAID)\|National Institutes of Health Clinical Center (CC)	Crohn´s Disease	October 30, 2017	Phase 1\|Phase 2
NCT00976183	Gynecologic Oncology Associates\|Merck Sharp & Dohme LLC	Ovarian Neoplasms	October 2009	Phase 1\|Phase 2
NCT00132002	National Cancer Institute (NCI)	Male Breast Cancer\|Recurrent Breast Cancer\|Stage IV Breast Cancer	June 2005	Phase 2
NCT01130506	National Cancer Institute (NCI)	Previously Treated Myelodysplastic Syndrome\|Recurrent Adult Acute Myeloid Leukemia\|Refractory Acute Myeloid Leukemia\|Secondary Acute Myeloid Leukemia\|Therapy-Related Acute Myeloid Leukemia\|Untreated Adult Acute Myeloid Leukemia	May 17, 2010	Phase 1
NCT00481078	National Cancer Institute (NCI)	Recurrent Non-small Cell Lung Cancer\|Stage IIIB Non-small Cell Lung Cancer\|Stage IV Non-small Cell Lung Cancer	May 2007	Phase 2
NCT01294670	Memorial Sloan Kettering Cancer Center\|Merck Sharp & Dohme LLC\|Phoenix Children´s Hospital\|Milton S. Hershey Medical Center\|Johns Hopkins University\|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|Children´s Hospital Colorado\|University of Florida\|Alberta Children´s Hospital\|M.D. Anderson Cancer Center\|Dana-Farber Cancer Institute\|Children´s Mercy Hospital & Clinics\|Johns Hopkins All Children´s Hospital\|Arnold Palmer Hospital for Children	Solid Tumors\|Relapsed+Refractory Sarcomas	February 9, 2011	Phase 1\|Phase 2
NCT01695057	University of Southern California\|National Cancer Institute (NCI)	Stage II Breast Cancer\|Stage IIIA Breast Cancer\|Triple-negative Breast Cancer	October 2012	Not Applicable
NCT00138177	National Cancer Institute (NCI)	Recurrent Colon Cancer\|Recurrent Rectal Cancer\|Stage III Colon Cancer\|Stage III Rectal Cancer\|Stage IV Colon Cancer\|Stage IV Rectal Cancer\|Unspecified Adult Solid Tumor, Protocol Specific	July 2005	Phase 1
NCT01554852	University of Leeds\|Celgene\|Merck Sharp & Dohme LLC\|Amgen	Multiple Myeloma	May 2010	Phase 3
NCT00097929	Merck Sharp & Dohme LLC	B-cell Lymphoma	May 1, 2005	Phase 2
NCT01353482	University College, London\|Merck Sharp & Dohme LLC	Malignant Pleural Mesothelioma		Phase 1\|Phase 2
NCT01342757	National Cancer Institute (NCI)	Adult Glioblastoma\|Depression\|Recurrent Adult Brain Tumor	December 2010	Not Applicable
NCT03426891	H. Lee Moffitt Cancer Center and Research Institute\|Merck Sharp & Dohme LLC	Glioblastoma\|Brain Tumor\|GBM	March 16, 2018	Phase 1
NCT02475915	South East Asia Research Collaboration with Hawaii\|The Thai Red Cross AIDS Research Centre\|Cooper Human Systems	Acute HIV Infection	January 2015	Phase 1\|Phase 2
NCT01175980	National Cancer Institute (NCI)	Recurrent Oral Cavity Adenoid Cystic Carcinoma\|Recurrent Salivary Gland Carcinoma\|Salivary Gland Adenoid Cystic Carcinoma\|Stage III Major Salivary Gland Cancer AJCC v7\|Stage III Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7\|Stage IVA Major Salivary Gland Cancer AJCC v7\|Stage IVA Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7\|Stage IVB Major Salivary Gland Cancer AJCC v7\|Stage IVB Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7\|Stage IVC Major Salivary Gland Cancer AJCC v7\|Stage IVC Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7\|Tongue Carcinoma	August 6, 2010	Phase 2
NCT00667082	Celgene	Non-Small Cell Lung Cancer\|Pancreatic Cancer\|Melanoma\|Lymphoma\|Multiple Myeloma	March 2008	Phase 1
NCT01312818	Masonic Cancer Center, University of Minnesota\|Millennium Pharmaceuticals, Inc.	Acute Lymphoblastic Leukemia	June 2011	Phase 2
NCT00992446	Fred Hutchinson Cancer Center\|National Cancer Institute (NCI)	Adult Diffuse Large B-Cell Lymphoma\|B-Cell Non-Hodgkin Lymphoma\|Follicular Lymphoma\|Mantle Cell Lymphoma\|Non-Hodgkin Lymphoma\|T-Cell Non-Hodgkin Lymphoma	September 2, 2010	Phase 2
NCT00310024	National Cancer Institute (NCI)	Refractory Multiple Myeloma\|Stage I Multiple Myeloma\|Stage II Multiple Myeloma\|Stage III Multiple Myeloma	November 2005	Phase 1
NCT00798720	University of Wisconsin, Madison\|Millennium Pharmaceuticals, Inc.\|Merck Sharp & Dohme LLC	Carcinoma, Non Small Cell Lung	December 2008	Phase 2
NCT00821951	Yale University\|Merck Sharp & Dohme LLC	Non-Small Cell Lung Cancer (NSCLC)	May 2009	Phase 1
NCT00791011	Amgen	Hodgkin´s Lymphoma\|Low Grade Lymphoma\|Lymphoma\|Mantle Cell Lymphoma\|Non-Hodgkin´s Lymphoma\|Diffuse Large Cell Lymphoma	February 2008	Phase 1
NCT01076530	National Cancer Institute (NCI)	Childhood Atypical Teratoid+Rhabdoid Tumor\|Childhood Central Nervous System Choriocarcinoma\|Childhood Central Nervous System Embryonal Tumor\|Childhood Central Nervous System Germinoma\|Childhood Central Nervous System Mixed Germ Cell Tumor\|Childhood Central Nervous System Teratoma\|Childhood Central Nervous System Yolk Sac Tumor\|Childhood Choroid Plexus Tumor\|Childhood Craniopharyngioma\|Childhood Ependymoblastoma\|Childhood Grade I Meningioma\|Childhood Grade II Meningioma\|Childhood Grade III Meningioma\|Childhood High-grade Cerebellar Astrocytoma\|Childhood High-grade Cerebral Astrocytoma\|Childhood Infratentorial Ependymoma\|Childhood Low-grade Cerebellar Astrocytoma\|Childhood Low-grade Cerebral Astrocytoma\|Childhood Medulloepithelioma\|Childhood Mixed Glioma\|Childhood Oligodendroglioma\|Childhood Supratentorial Ependymoma\|Extra-adrenal Paraganglioma\|Recurrent Childhood Brain Stem Glioma\|Recurrent Childhood Central Nervous System Embryonal Tumor\|Recurrent Childhood Cerebellar Astrocytoma\|Recurrent Childhood Cerebral Astrocytoma\|Recurrent Childhood Ependymoma\|Recurrent Childhood Medulloblastoma\|Recurrent Childhood Pineoblastoma\|Recurrent Childhood Spinal Cord Neoplasm\|Recurrent Childhood Subependymal Giant Cell Astrocytoma\|Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor\|Recurrent Childhood Visual Pathway and Hypothalamic Glioma	February 2010	Phase 1
NCT00561418	Ohio State University Comprehensive Cancer Center\|Merck Sharp & Dohme LLC	Lymphoma\|Small Intestine Cancer	November 2007	Phase 1
NCT01983969	M.D. Anderson Cancer Center	Advanced Cancers\|Lymphoma	November 7, 2013	Phase 1\|Phase 2
NCT02619253	Nabil Adra\|Indiana University	Renal Cell Carcinoma\|Urinary Bladder Neoplasms	February 23, 2016	Phase 1
NCT00275080	National Cancer Institute (NCI)	Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities\|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)\|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)\|Blastic Phase Chronic Myelogenous Leukemia\|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue\|Nodal Marginal Zone B-cell Lymphoma\|Recurrent Adult Acute Lymphoblastic Leukemia\|Recurrent Adult Acute Myeloid Leukemia\|Recurrent Adult Burkitt Lymphoma\|Recurrent Adult Diffuse Large Cell Lymphoma\|Recurrent Adult Diffuse Mixed Cell Lymphoma\|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma\|Recurrent Adult Immunoblastic Large Cell Lymphoma\|Recurrent Adult Lymphoblastic Lymphoma\|Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Grade 3 Follicular Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Marginal Zone Lymphoma\|Recurrent Small Lymphocytic Lymphoma\|Secondary Acute Myeloid Leukemia\|Splenic Marginal Zone Lymphoma\|Stage III Adult Burkitt Lymphoma\|Stage III Adult Diffuse Large Cell Lymphoma\|Stage III Adult Diffuse Mixed Cell Lymphoma\|Stage III Adult Diffuse Small Cleaved Cell Lymphoma\|Stage III Adult Immunoblastic Large Cell Lymphoma\|Stage III Adult Lymphoblastic Lymphoma\|Stage III Grade 1 Follicular Lymphoma\|Stage III Grade 2 Follicular Lymphoma\|Stage III Grade 3 Follicular Lymphoma\|Stage III Mantle Cell Lymphoma\|Stage III Marginal Zone Lymphoma\|Stage III Small Lymphocytic Lymphoma\|Stage IV Adult Burkitt Lymphoma\|Stage IV Adult Diffuse Large Cell Lymphoma\|Stage IV Adult Diffuse Mixed Cell Lymphoma\|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma\|Stage IV Adult Immunoblastic Large Cell Lymphoma\|Stage IV Adult Lymphoblastic Lymphoma\|Stage IV Grade 1 Follicular Lymphoma\|Stage IV Grade 2 Follicular Lymphoma\|Stage IV Grade 3 Follicular Lymphoma\|Stage IV Mantle Cell Lymphoma\|Stage IV Marginal Zone Lymphoma\|Stage IV Small Lymphocytic Lymphoma\|Unspecified Adult Solid Tumor, Protocol Specific\|Untreated Adult Acute Lymphoblastic Leukemia\|Untreated Adult Acute Myeloid Leukemia	February 2006	Phase 1
NCT01790568	University of Michigan Rogel Cancer Center	Graft vs Host Disease\|Hematologic Neoplasms\|Non-Neoplastic Hematologic and Lymphocytic Disorder	December 2014	Phase 2
NCT00473889	Merck Sharp & Dohme LLC	Stage IIIB or IV Non-Small Cell Lung Cancer	May 2007	Phase 2\|Phase 3
NCT00776503	Groupe Francophone des Myelodysplasies\|Merck Sharp & Dohme LLC	Myelodysplastic Syndromes	May 2008	Phase 1\|Phase 2
NCT00134043	National Cancer Institute (NCI)	Insular Thyroid Cancer\|Recurrent Thyroid Cancer\|Stage II Follicular Thyroid Cancer\|Stage II Papillary Thyroid Cancer\|Stage IV Follicular Thyroid Cancer\|Stage IV Papillary Thyroid Cancer\|Thyroid Gland Medullary Carcinoma	December 2005	Phase 2
NCT01789255	National Cancer Institute (NCI)	Accelerated Phase Chronic Myelogenous Leukemia\|Adult Acute Myeloid Leukemia in Remission\|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities\|Adult Acute Myeloid Leukemia With Del(5q)\|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)\|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)\|Adult Grade III Lymphomatoid Granulomatosis\|B-cell Chronic Lymphocytic Leukemia\|Chronic Myelogenous Leukemia, BCR-ABL1 Positive\|Chronic Myelomonocytic Leukemia\|Chronic Phase Chronic Myelogenous Leukemia\|Contiguous Stage II Adult Burkitt Lymphoma\|Contiguous Stage II Adult Diffuse Large Cell Lymphoma\|Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma\|Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma\|Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma\|Contiguous Stage II Adult Lymphoblastic Lymphoma\|Contiguous Stage II Grade 1 Follicular Lymphoma\|Contiguous Stage II Grade 2 Follicular Lymphoma\|Contiguous Stage II Grade 3 Follicular Lymphoma\|Contiguous Stage II Mantle Cell Lymphoma\|Contiguous Stage II Marginal Zone Lymphoma\|Contiguous Stage II Small Lymphocytic Lymphoma\|Cutaneous B-cell Non-Hodgkin Lymphoma\|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue\|Graft Versus Host Disease\|Intraocular Lymphoma\|Myelodysplastic Syndrome With Isolated Del(5q)\|Myelodysplastic+Myeloproliferative Neoplasm, Unclassifiable\|Nodal Marginal Zone B-cell Lymphoma\|Noncontiguous Stage II Adult Burkitt Lymphoma\|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma\|Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma\|Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma\|Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma\|Noncontiguous Stage II Adult Lymphoblastic Lymphoma\|Noncontiguous Stage II Grade 1 Follicular Lymphoma\|Noncontiguous Stage II Grade 2 Follicular Lymphoma\|Noncontiguous Stage II Grade 3 Follicular Lymphoma\|Noncontiguous Stage II Mantle Cell Lymphoma\|Noncontiguous Stage II Marginal Zone Lymphoma\|Noncontiguous Stage II Small Lymphocytic Lymphoma\|Post-transplant Lymphoproliferative Disorder\|Primary Central Nervous System Hodgkin Lymphoma\|Primary Central Nervous System Non-Hodgkin Lymphoma\|Recurrent Adult Acute Myeloid Leukemia\|Recurrent Adult Burkitt Lymphoma\|Recurrent Adult Diffuse Large Cell Lymphoma\|Recurrent Adult Diffuse Mixed Cell Lymphoma\|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma\|Recurrent Adult Grade III Lymphomatoid Granulomatosis\|Recurrent Adult Hodgkin Lymphoma\|Recurrent Adult Immunoblastic Large Cell Lymphoma\|Recurrent Adult Lymphoblastic Lymphoma\|Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Grade 3 Follicular Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Marginal Zone Lymphoma\|Recurrent Small Lymphocytic Lymphoma\|Refractory Anemia\|Refractory Anemia With Excess Blasts\|Refractory Anemia With Ringed Sideroblasts\|Refractory Chronic Lymphocytic Leukemia\|Refractory Cytopenia With Multilineage Dysplasia\|Refractory Hairy Cell Leukemia\|Relapsing Chronic Myelogenous Leukemia\|Secondary Central Nervous System Hodgkin Lymphoma\|Secondary Central Nervous System Non-Hodgkin Lymphoma\|Small Intestine Lymphoma\|Splenic Marginal Zone Lymphoma\|Stage I Adult Burkitt Lymphoma\|Stage I Adult Diffuse Large Cell Lymphoma\|Stage I Adult Diffuse Mixed Cell Lymphoma\|Stage I Adult Diffuse Small Cleaved Cell Lymphoma\|Stage I Adult Hodgkin Lymphoma\|Stage I Adult Immunoblastic Large Cell Lymphoma\|Stage I Adult Lymphoblastic Lymphoma\|Stage I Chronic Lymphocytic Leukemia\|Stage I Grade 1 Follicular Lymphoma\|Stage I Grade 2 Follicular Lymphoma\|Stage I Grade 3 Follicular Lymphoma\|Stage I Mantle Cell Lymphoma\|Stage I Marginal Zone Lymphoma\|Stage I Small Lymphocytic Lymphoma\|Stage II Adult Hodgkin Lymphoma\|Stage II Chronic Lymphocytic Leukemia\|Stage III Adult Burkitt Lymphoma\|Stage III Adult Diffuse Large Cell Lymphoma\|Stage III Adult Diffuse Mixed Cell Lymphoma\|Stage III Adult Diffuse Small Cleaved Cell Lymphoma\|Stage III Adult Hodgkin Lymphoma\|Stage III Adult Immunoblastic Large Cell Lymphoma\|Stage III Adult Lymphoblastic Lymphoma\|Stage III Chronic Lymphocytic Leukemia\|Stage III Grade 1 Follicular Lymphoma\|Stage III Grade 2 Follicular Lymphoma\|Stage III Grade 3 Follicular Lymphoma\|Stage III Mantle Cell Lymphoma\|Stage III Marginal Zone Lymphoma\|Stage IV Adult Burkitt Lymphoma\|Stage IV Adult Diffuse Large Cell Lymphoma\|Stage IV Adult Diffuse Mixed Cell Lymphoma\|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma\|Stage IV Adult Hodgkin Lymphoma\|Stage IV Adult Immunoblastic Large Cell Lymphoma\|Stage IV Adult Lymphoblastic Lymphoma\|Stage IV Chronic Lymphocytic Leukemia\|Stage IV Grade 1 Follicular Lymphoma\|Stage IV Grade 2 Follicular Lymphoma\|Stage IV Grade 3 Follicular Lymphoma\|Stage IV Mantle Cell Lymphoma\|Stage IV Marginal Zone Lymphoma\|Stage IV Small Lymphocytic Lymphoma\|Testicular Lymphoma\|Waldenström Macroglobulinemia	June 2013	Phase 2
NCT00703664	National Cancer Institute (NCI)	Recurrent Mantle Cell Lymphoma\|Recurrent Non-Hodgkin Lymphoma	July 9, 2008	Phase 2
NCT01087554	M.D. Anderson Cancer Center	Advanced Cancer	March 2010	Phase 1
NCT00948688	Massachusetts General Hospital\|Dana-Farber Cancer Institute\|Brigham and Women´s Hospital\|Merck Sharp & Dohme LLC	Pancreatic Cancer\|Adenocarcinoma of the Pancreas	August 2009	Phase 1\|Phase 2
NCT00368875	National Cancer Institute (NCI)	Male Breast Cancer\|Stage IIIB Breast Cancer\|Stage IIIC Breast Cancer\|Stage IV Breast Cancer	July 2006	Phase 1\|Phase 2
NCT01132911	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	Lymphoma\|Sarcoma\|WilmsTumor\|Neuroblastoma	May 10, 2010	Phase 1
NCT04357873	UNICANCER\|Merck Sharp & Dohme LLC\|Fondation ARC\|ERA-NET	Squamous Cell Lung Cancer\|Vulvar Cancer\|Penile Cancer\|Cervix Cancer\|Head and Neck Squamous Cell Carcinoma\|Anal Cancer	October 28, 2020	Phase 2
NCT03263533	Virginia Commonwealth University	Schizophrenia	April 2017	Early Phase 1
NCT02316340	The University of Texas Health Science Center at San Antonio	Colorectal Cancer	February 11, 2015	Phase 2
NCT00697476	Armando Santoro, MD\|Istituto Clinico Humanitas	Small Cell Lung Cancer	January 2009	Phase 1\|Phase 2
NCT00948064	M.D. Anderson Cancer Center\|Merck Sharp & Dohme LLC\|Celgene Corporation	Leukemia	September 8, 2009	Phase 2
NCT03117751	St. Jude Children´s Research Hospital\|Incyte Corporation\|Amgen\|Servier	Acute Lymphoblastic Leukemia\|Acute Lymphoblastic Lymphoma	March 29, 2017	Phase 2\|Phase 3
NCT01578343	Samsung Medical Center\|Seok Jin Kim	Mantle Cell Lymphoma	June 2012	Phase 2
NCT01319383	University of North Carolina, Chapel Hill\|National Institutes of Health (NIH)\|Merck Sharp & Dohme LLC\|National Institute of Allergy and Infectious Diseases (NIAID)	HIV-1 Infection	February 2011	Phase 1\|Phase 2
NCT01738646	Duke University\|Genentech, Inc.\|Merck Sharp & Dohme LLC	Recurrent Glioblastoma Multiforme\|Malignant Glioma\|Adult Brain Tumor	January 2013	Phase 2
NCT00983268	Vanderbilt-Ingram Cancer Center\|National Cancer Institute (NCI)\|National Comprehensive Cancer Network	Pancreatic Cancer\|Periampullary Adenocarcinoma	October 2009	Phase 1
NCT03894826	University of Calgary	Refractory Epilepsy	December 10, 2018	Phase 2
NCT00091559	Merck Sharp & Dohme LLC	Cutaneous T-cell Lymphoma\|Sezary Syndrome\|Mycosis Fungoides	February 3, 2005	Phase 2
NCT01266057	M.D. Anderson Cancer Center	Advanced Cancers	April 28, 2011	Phase 1
NCT00801151	Institut Claudius Regaud\|Merck Sharp & Dohme LLC	Malignant Solid Tumour	January 2009	Phase 1
NCT00106626	Merck Sharp & Dohme LLC	Advanced Cancer	August 2005	Phase 1
NCT00656617	M.D. Anderson Cancer Center\|Merck Sharp & Dohme LLC	Acute Myeloid Leukemia (AML)\|Myelodysplastic Syndrome (MDS)	April 2008	Phase 2
NCT03561259	Jubilant DraxImage Inc.	Neuroblastoma\|Neuroectodermal Tumors\|Neoplasms	October 21, 2019	Phase 2
NCT00958074	University of Washington\|National Cancer Institute (NCI)	Cutaneous T-cell Lymphoma Stage I\|Cutaneous T-cell Lymphoma Stage II\|Cutaneous T-cell Lymphoma Stage III\|Cutaneous T-cell Lymphoma Stage IV	July 2009	Phase 2
NCT00731731	National Cancer Institute (NCI)	Adult Giant Cell Glioblastoma\|Adult Glioblastoma\|Adult Gliosarcoma	July 10, 2009	Phase 1\|Phase 2
NCT00324480	National Cancer Institute (NCI)	Unspecified Adult Solid Tumor, Protocol Specific	March 2006	Phase 1
NCT03056495	German Center for Neurodegenerative Diseases (DZNE)\|University Hospital, Bonn\|University of Göttingen	Alzheimer Disease	September 28, 2017	Phase 1
NCT00731952	University of Virginia	Non Small Cell Lung Cancer	June 2006	Phase 1
NCT01492881	UNC Lineberger Comprehensive Cancer Center\|Merck Sharp & Dohme LLC	Multiple Myeloma	April 2012	Phase 2
NCT01748240	Groupe Francophone des Myelodysplasies\|Merck Sharp & Dohme LLC	Myelodysplastic Syndrome	March 2013	Phase 2
NCT03842696	University of Michigan Rogel Cancer Center\|National Institutes of Health (NIH)	Hematologic Diseases\|Acute Leukemia in Remission\|Chronic Myelogenous Leukemia - Chronic Phase\|Chronic Myelogenous Leukemia, Accelerated Phase\|Chronic Myelogenous Leukemia, Blastic Phase\|Myelodysplastic Syndromes\|Mantle Cell Lymphoma\|Follicular Lymphoma\|Diffuse Large B Cell Lymphoma\|Non Hodgkin Lymphoma\|Graft Vs Host Disease\|Graft-versus-host-disease	February 4, 2020	Phase 1\|Phase 2
NCT01587352	National Cancer Institute (NCI)\|Institut Curie Paris\|Memorial Sloan Kettering Cancer Center\|Moffitt Cancer Center P2C	Metastatic Uveal Melanoma\|Stage IV Uveal Melanoma AJCC v7	April 20, 2012	Phase 2
NCT00455351	Oslo University Hospital	Pelvic Cancer\|Radiotherapy	February 2007	Phase 1
NCT00424775	Merck Sharp & Dohme LLC	Neoplasms	January 2007	Phase 1
NCT01501370	Tiziana Marangon\|University of Turin, Italy	Multiple Myeloma	January 2012	Phase 2
NCT00946673	Stanford University\|National Comprehensive Cancer Network	Brain Cancer\|Neoplasm Metastasis\|Lung Cancer\|Carcinoma, Non-Small-Cell Lung	June 2009	Phase 1
NCT01059552	Fox Chase Cancer Center\|National Comprehensive Cancer Network	Locally Advanced Non-small Cell Lung Cancer	December 16, 2009	Phase 1
NCT02083250	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Acute Lymphoblastic Leukemia in Remission\|Acute Myeloid Leukemia in Remission\|Allogeneic Hematopoietic Stem Cell Transplantation Recipient\|Myelodysplastic Syndrome\|Previously Treated Myelodysplastic Syndrome\|Recurrent Acute Lymphoblastic Leukemia\|Recurrent Acute Myeloid Leukemia	March 6, 2014	Phase 1
NCT01266031	National Cancer Institute (NCI)\|M.D. Anderson Cancer Center\|Genentech, Inc.\|Merck Sharp & Dohme LLC\|Brain Tumor Trials Collaborative\|Ohio State University Wexner Medical Center\|Northwestern University Feinberg School of Medicine\|UF Health Cancer Center at Orlando Health\|Baylor Health Care System\|MUSC Hollings Cancer Center\|University of Utah Health System\|University of Washington\|Henry Ford Health System\|Columbia University\|Rush University Medical Center\|NorthShore University HealthSystem\|The Cleveland Clinic\|University of North Carolina, Chapel Hill\|Washington University School of Medicine\|Texas Oncology-Austin\|National Institutes of Health Clinical Center (CC)	Malignant Glioma\|Recurrent Glioblastoma	July 12, 2011	Phase 1\|Phase 2
NCT00837174	The Methodist Hospital Research Institute	Non-Hodgkin Lymphoma	June 2010	Phase 2
NCT01118975	University of Maryland, Baltimore\|University of Maryland Greenebaum Cancer Center	Breast Cancer\|Neoplasm Metastasis	March 2010	Phase 1\|Phase 2
NCT00262834	National Cancer Institute (NCI)	Breast Cancer\|Stage I Breast Cancer\|Stage II Breast Cancer\|Stage III Breast Cancer	October 2005	Phase 2
NCT01500538	Peter MacCallum Cancer Centre, Australia\|GlaxoSmithKline\|Merck Sharp & Dohme LLC	Follicular Lymphoma\|Marginal Zone Lymphoma\|Mantle Cell Lymphoma	October 2012	Phase 2
NCT04324099	University Hospital, Basel, Switzerland\|Swiss National Science Foundation	Autism-Spectrum Disorder\|Conduct Disorder	July 16, 2020
NCT00641706	National Cancer Institute (NCI)	Adult Giant Cell Glioblastoma\|Adult Glioblastoma\|Adult Gliosarcoma\|Recurrent Adult Brain Tumor	July 2008	Phase 2
NCT03742245	The Methodist Hospital Research Institute\|AstraZeneca	Breast Cancer Metastatic\|Breast Cancer	June 11, 2019	Phase 1
NCT05317403	Medical College of Wisconsin	Acute Myeloid Leukemia, in Relapse\|Acute Myeloid Leukemia Refractory	July 2022	Phase 1
NCT03263936	Therapeutic Advances in Childhood Leukemia Consortium	Acute Myelogenous Leukemia	July 11, 2017	Phase 1
NCT01249443	AIDS Malignancy Consortium\|National Cancer Institute (NCI)\|The Emmes Company, LLC\|University of Arkansas	HIV Infection\|Recurrent Anal Cancer\|Recurrent Breast Cancer\|Recurrent Esophageal Cancer\|Recurrent Gastric Cancer\|Recurrent Metastatic Squamous Neck Cancer With Occult Primary\|Recurrent Non-small Cell Lung Cancer\|Recurrent Ovarian Epithelial Cancer\|Recurrent Salivary Gland Cancer\|Recurrent Squamous Cell Carcinoma of the Hypopharynx\|Recurrent Squamous Cell Carcinoma of the Larynx\|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity\|Recurrent Squamous Cell Carcinoma of the Nasopharynx\|Recurrent Squamous Cell Carcinoma of the Oropharynx\|Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity\|Recurrent Verrucous Carcinoma of the Larynx\|Recurrent Verrucous Carcinoma of the Oral Cavity\|Salivary Gland Squamous Cell Carcinoma\|Stage IV Anal Cancer\|Stage IV Breast Cancer\|Stage IV Esophageal Cancer\|Stage IV Gastric Cancer\|Stage IV Non-small Cell Lung Cancer\|Stage IV Ovarian Epithelial Cancer\|Stage IV Salivary Gland Cancer\|Stage IV Squamous Cell Carcinoma of the Hypopharynx\|Stage IV Squamous Cell Carcinoma of the Larynx\|Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity\|Stage IV Squamous Cell Carcinoma of the Nasopharynx\|Stage IV Squamous Cell Carcinoma of the Oropharynx\|Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity\|Stage IV Verrucous Carcinoma of the Larynx\|Stage IV Verrucous Carcinoma of the Oral Cavity\|Unspecified Adult Solid Tumor, Protocol Specific	November 2013	Phase 1
NCT01802333	National Cancer Institute (NCI)	Acute Myeloid Leukemia\|Untreated Adult Acute Myeloid Leukemia	February 12, 2013	Phase 3
NCT00882206	Masonic Cancer Center, University of Minnesota	Leukemia\|Lymphoma	April 2009	Phase 2
NCT01550224	Steven E. Coutre\|Merck Sharp & Dohme LLC\|Stanford University	Acute Myeloid Leukemia With 11q23-abnormality in Relapse	May 1, 2013	Phase 2
NCT00810602	Pavan Reddy, MD\|University of Michigan Rogel Cancer Center	Hematologic Malignancies\|Graft vs Host Disease	January 2009	Phase 1\|Phase 2
NCT01600742	National Taiwan University Hospital	Brain Metastasis	August 2012	Phase 2
NCT00278395	National Cancer Institute (NCI)	Recurrent Renal Cell Carcinoma\|Stage IV Renal Cell Cancer	October 2005	Phase 2
NCT00729118	Ohio State University Comprehensive Cancer Center\|Merck Sharp & Dohme LLC	Multiple Myeloma\|Plasma Cell Neoplasm	September 26, 2008	Phase 1
NCT00111813	Merck Sharp & Dohme LLC	Multiple Myeloma	September 2005	Phase 1
NCT01567709	National Cancer Institute (NCI)	Adult B Acute Lymphoblastic Leukemia\|Adult T Acute Lymphoblastic Leukemia\|Anaplastic Large Cell Lymphoma\|Angioimmunoblastic T-Cell Lymphoma\|Chronic Lymphocytic Leukemia\|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue\|Hepatosplenic T-Cell Lymphoma\|Intraocular Lymphoma\|Lymphomatous Involvement of Non-Cutaneous Extranodal Site\|Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma\|Nodal Marginal Zone Lymphoma\|Primary Cutaneous B-Cell Non-Hodgkin Lymphoma\|Recurrent Adult Acute Lymphoblastic Leukemia\|Recurrent Adult Burkitt Lymphoma\|Recurrent Adult Grade III Lymphomatoid Granulomatosis\|Recurrent Adult Hodgkin Lymphoma\|Recurrent Adult Immunoblastic Lymphoma\|Recurrent Adult Lymphoblastic Lymphoma\|Recurrent Adult T-Cell Leukemia+Lymphoma\|Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Grade 3 Follicular Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Marginal Zone Lymphoma\|Recurrent Mycosis Fungoides and Sezary Syndrome\|Recurrent Non-Hodgkin Lymphoma\|Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma\|Recurrent Small Lymphocytic Lymphoma\|Refractory Chronic Lymphocytic Leukemia\|Refractory Hairy Cell Leukemia\|Small Intestinal Lymphoma\|Splenic Marginal Zone Lymphoma\|T-Cell Large Granular Lymphocyte Leukemia\|Testicular Lymphoma\|Waldenstrom Macroglobulinemia	April 16, 2012	Phase 1
NCT03843528	Johns Hopkins All Children´s Hospital	Acute Myeloid Leukemia\|Myelodysplastic Syndromes\|Mixed Phenotype Acute Leukemia\|Juvenile Myelomonocytic Leukemia	May 1, 2019	Phase 1
NCT00662311	University of Washington\|National Cancer Institute (NCI)	Stage IIIA Non-small Cell Lung Cancer\|Stage IIIB Non-small Cell Lung Cancer	March 2008	Phase 1\|Phase 2
NCT01386398	European Organisation for Research and Treatment of Cancer - EORTC	Lymphoma		Phase 3
NCT00217412	National Cancer Institute (NCI)	Childhood Acute Promyelocytic Leukemia (M3)\|Childhood Atypical Teratoid+Rhabdoid Tumor\|Childhood Burkitt Lymphoma\|Childhood Chronic Myelogenous Leukemia\|Childhood Diffuse Large Cell Lymphoma\|Childhood Immunoblastic Large Cell Lymphoma\|Juvenile Myelomonocytic Leukemia\|Recurrent Childhood Acute Lymphoblastic Leukemia\|Recurrent Childhood Acute Myeloid Leukemia\|Recurrent Childhood Grade III Lymphomatoid Granulomatosis\|Recurrent Childhood Large Cell Lymphoma\|Recurrent Childhood Lymphoblastic Lymphoma\|Recurrent Childhood Medulloblastoma\|Recurrent Childhood Small Noncleaved Cell Lymphoma\|Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor\|Recurrent Neuroblastoma\|Recurrent+Refractory Childhood Hodgkin Lymphoma\|Relapsing Chronic Myelogenous Leukemia\|Unspecified Childhood Solid Tumor, Protocol Specific	August 2005	Phase 1
NCT00895934	National Cancer Institute (NCI)	Adult Acute Megakaryoblastic Leukemia (M7)\|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)\|Adult Acute Monoblastic Leukemia (M5a)\|Adult Acute Monocytic Leukemia (M5b)\|Adult Acute Myeloblastic Leukemia With Maturation (M2)\|Adult Acute Myeloblastic Leukemia Without Maturation (M1)\|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities\|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)\|Adult Acute Myelomonocytic Leukemia (M4)\|Adult Erythroleukemia (M6a)\|Adult Pure Erythroid Leukemia (M6b)\|Recurrent Adult Acute Myeloid Leukemia	May 2009	Phase 1\|Phase 2
NCT01038388	Emory University\|Merck Sharp & Dohme LLC\|Celgene Corporation	Multiple Myeloma	January 15, 2010	Phase 1
NCT02553460	St. Jude Children´s Research Hospital\|Gateway for Cancer Research\|Baylor College of Medicine	Acute Lymphoblastic Leukemia	January 29, 2016	Phase 1\|Phase 2
NCT02559778	Wake Forest University Health Sciences\|Dell, Inc.\|Beat NB Cancer Foundation\|K C Pharmaceuticals Inc.\|Team Parker for Life	Neuroblastoma	September 2015	Phase 2
NCT01116154	City of Hope Medical Center	Adult Nasal Type Extranodal NK+T-cell Lymphoma\|Anaplastic Large Cell Lymphoma\|Angioimmunoblastic T-cell Lymphoma\|Cutaneous B-cell Non-Hodgkin Lymphoma\|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue\|Hepatosplenic T-cell Lymphoma\|Intraocular Lymphoma\|Nodal Marginal Zone B-cell Lymphoma\|Peripheral T-Cell Lymphoma\|Post-transplant Lymphoproliferative Disorder\|Recurrent Adult Burkitt Lymphoma\|Recurrent Adult Diffuse Large Cell Lymphoma\|Recurrent Adult Diffuse Mixed Cell Lymphoma\|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma\|Recurrent Adult Grade III Lymphomatoid Granulomatosis\|Recurrent Adult Hodgkin Lymphoma\|Recurrent Adult Immunoblastic Large Cell Lymphoma\|Recurrent Adult Lymphoblastic Lymphoma\|Recurrent Adult T-cell Leukemia+Lymphoma\|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma\|Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Grade 3 Follicular Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Marginal Zone Lymphoma\|Recurrent Mycosis Fungoides+Sezary Syndrome\|Recurrent Small Lymphocytic Lymphoma\|Small Intestine Lymphoma\|Splenic Marginal Zone Lymphoma\|Testicular Lymphoma\|Waldenstrom Macroglobulinemia	May 2010	Phase 1
NCT01394354	University Hospital Freiburg\|Merck Sharp & Dohme LLC\|Janssen-Cilag Ltd.	Multiple Myeloma in Relapse	August 2011	Phase 1\|Phase 2
NCT00787527	M.D. Anderson Cancer Center\|Merck Sharp & Dohme LLC	Lymphoma	November 2008	Phase 1\|Phase 2
NCT00772798	Herlev Hospital\|Odense University Hospital	Ovarian Cancer	June 2007	Phase 2
NCT00045006	Memorial Sloan Kettering Cancer Center\|National Cancer Institute (NCI)	Cancer	July 2001	Phase 1
NCT00373490	Merck Sharp & Dohme LLC	Tumors	July 2006	Phase 1
NCT02336074	Imperial College London\|Medical Research Council\|University of Oxford\|University of Cambridge\|Chelsea and Westminster NHS Foundation Trust\|Royal Free Hospital NHS Foundation Trust\|Brighton and Sussex University Hospitals NHS Trust\|Guy´s and St Thomas´ NHS Foundation Trust\|Central and North West London NHS Foundation Trust	HIV	November 27, 2015	Phase 2
NCT00838929	Sidney Kimmel Cancer Center at Thomas Jefferson University\|Merck Sharp & Dohme LLC\|Thomas Jefferson University	Brain Metastases	March 2009	Phase 1
NCT00243100	National Cancer Institute (NCI)	Unspecified Adult Solid Tumor, Protocol Specific	November 2005	Phase 1
NCT01720602	University of Washington\|National Cancer Institute (NCI)	Male Breast Cancer\|Recurrent Breast Cancer\|Stage IV Breast Cancer	November 2012	Not Applicable
NCT00942266	Roswell Park Cancer Institute\|Merck Sharp & Dohme LLC	Adenocarcinoma of the Colon\|Adenocarcinoma of the Rectum\|Recurrent Colon Cancer\|Recurrent Rectal Cancer\|Stage IV Colon Cancer\|Stage IV Rectal Cancer	July 2009	Phase 2
NCT00416130	National University Hospital, Singapore\|Merck Sharp & Dohme LLC	Breast Cancer	January 2007	Phase 1\|Phase 2
NCT00810576	M.D. Anderson Cancer Center\|Merck Sharp & Dohme LLC	Lymphoma	January 2009	Phase 2
NCT00773747	Merck Sharp & Dohme LLC	Multiple Myeloma	December 1, 2008	Phase 3
NCT00392353	National Cancer Institute (NCI)	Acute Erythroid Leukemia\|Acute Megakaryoblastic Leukemia\|Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome\|Chronic Myelomonocytic Leukemia\|Myelodysplastic Syndrome\|Myelodysplastic Syndrome With Excess Blasts\|Myelodysplastic Syndrome With Ring Sideroblasts\|Recurrent Adult Acute Myeloid Leukemia\|Refractory Anemia	November 22, 2006	Phase 1\|Phase 2
NCT00486720	Merck Sharp & Dohme LLC	Myelodysplastic Syndromes\|Blood Disease\|Bone Marrow Disease	June 2007	Phase 2
NCT00857324	Tiziana Marangon\|University of Turin, Italy	Multiple Myeloma	March 2009	Phase 1\|Phase 2
NCT03332667	New Approaches to Neuroblastoma Therapy Consortium\|United Therapeutics	Neuroblastoma	September 12, 2018	Phase 1
NCT00238303	National Cancer Institute (NCI)	Adult Giant Cell Glioblastoma\|Adult Glioblastoma\|Adult Gliosarcoma\|Recurrent Adult Brain Tumor	September 2005	Phase 2
NCT00132028	National Cancer Institute (NCI)	Adult Favorable Prognosis Hodgkin Lymphoma\|Adult Lymphocyte Depletion Hodgkin Lymphoma\|Adult Lymphocyte Predominant Hodgkin Lymphoma\|Adult Mixed Cellularity Hodgkin Lymphoma\|Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma\|Adult Nodular Sclerosis Hodgkin Lymphoma\|Adult Unfavorable Prognosis Hodgkin Lymphoma\|Recurrent Adult Hodgkin Lymphoma	September 2005	Phase 2
NCT00565227	University of Michigan Rogel Cancer Center	Non-Small-Cell Lung Carcinoma\|Prostate Cancer\|Bladder Cancer\|Urothelial Carcinoma	April 2007	Phase 1
NCT02943642	Angimmune LLC\|City of Hope National Medical Center\|Columbia University\|Dana-Farber Cancer Institute\|Northwestern University Feinberg School of Medicine\|H. Lee Moffitt Cancer Center and Research Institute\|Ohio State University Comprehensive Cancer Center\|Rush University Medical Center\|Scott and White Hospital & Clinic\|Yale University\|Stanford University\|Thomas Jefferson University\|University of Arkansas\|University of Colorado, Denver\|University of Texas Southwestern Medical Center\|University of Washington\|Vanderbilt University School of Medicine\|Washington University School of Medicine	Mycosis Fungoides	January 2017	Phase 2
NCT00831493	M.D. Anderson Cancer Center\|Merck Sharp & Dohme LLC	Pancreatic Cancer	May 2009	Phase 1\|Phase 2
NCT01153672	University of Washington\|National Cancer Institute (NCI)	Male Breast Cancer\|Recurrent Breast Cancer\|Stage IV Breast Cancer	November 2010	Not Applicable
NCT00744354	UNC Lineberger Comprehensive Cancer Center\|Merck Sharp & Dohme LLC\|Millennium Pharmaceuticals, Inc.\|Ortho Biotech, Inc.	Multiple Myeloma and Plasma Cell Neoplasm	October 2008	Phase 1
NCT02707900	University of North Carolina, Chapel Hill\|National Institute of Allergy and Infectious Diseases (NIAID)	HIV-1 Infection	March 2016	Phase 1
NCT00720876	City of Hope Medical Center\|National Cancer Institute (NCI)\|Merck Sharp & Dohme LLC	Lymphoma	July 23, 2008	Phase 2
NCT02108002	National Institute of Neurological Disorders and Stroke (NINDS)\|National Institutes of Health Clinical Center (CC)	Von Hippel-Lindau Disease	April 5, 2014	Phase 1
NCT03509207	Medical University of Graz	Leiomyosarcoma\|Endometrial Stromal Tumors\|Carcinosarcomas Uterine	December 14, 2017	Phase 2
NCT00121225	National Cancer Institute (NCI)	Ciliary Body and Choroid Melanoma, Medium+Large Size\|Extraocular Extension Melanoma\|Iris Melanoma\|Uveal Melanoma\|Recurrent Intraocular Melanoma\|Recurrent Melanoma\|Stage IV Melanoma	September 2005	Phase 2
NCT00138203	National Cancer Institute (NCI)	Recurrent Non-small Cell Lung Cancer\|Stage IIIB Non-small Cell Lung Cancer\|Stage IV Non-small Cell Lung Cancer	June 2005	Phase 2
NCT00109109	Merck Sharp & Dohme LLC	Multiple Myeloma	December 1, 2003	Phase 1
NCT03803605	University of North Carolina, Chapel Hill\|National Institute of Allergy and Infectious Diseases (NIAID)	HIV-1 Infection	February 12, 2019	Phase 1
NCT02836548	The Netherlands Cancer Institute	Melanoma\|Skin Neoplasms	June 2016	Phase 1\|Phase 2
NCT01339871	M.D. Anderson Cancer Center	Advanced Cancer	April 20, 2011	Phase 1
NCT00589472	National Cancer Institute (NCI)	Prostate Adenocarcinoma\|Stage I Prostate Cancer\|Stage IIA Prostate Cancer\|Stage IIB Prostate Cancer\|Stage III Prostate Cancer	November 2007	Phase 2
NCT01413750	National Cancer Institute (NCI)	Stage IIIA Non-Small Cell Lung Cancer\|Stage IIIB Non-Small Cell Lung Cancer\|Stage IV Non-Small Cell Lung Cancer	November 2010	Phase 1\|Phase 2
NCT01236560	National Cancer Institute (NCI)	Brain Stem Glioma\|Cerebral Astrocytoma\|Childhood Cerebellar Anaplastic Astrocytoma\|Childhood Cerebral Anaplastic Astrocytoma\|Childhood Spinal Cord Neoplasm	November 15, 2010	Phase 2\|Phase 3
NCT00788112	University of California, San Francisco\|National Cancer Institute (NCI)	Breast Cancer	July 2009	Phase 1
NCT03022565	University of Miami\|University of Miami Sylvester Comprehensive Cancer Center	Uveal Melanoma	January 2020	Early Phase 1
NCT00719875	Yale University\|Merck Sharp & Dohme LLC	Advanced Breast Cancer	December 2008	Phase 1
NCT00127101	Merck Sharp & Dohme LLC	Lymphoma	September 2005	Phase 1
NCT01593670	Masonic Cancer Center, University of Minnesota\|Mayo Clinic	Myelodysplastic Syndrome	March 2013	Phase 2
NCT00910000	Dana-Farber Cancer Institute\|Brigham and Women´s Hospital\|Massachusetts General Hospital\|Merck Sharp & Dohme LLC	Ovarian Cancer\|Fallopian Tube Cancer\|Peritoneal Cancer	June 2009	Phase 1\|Phase 2
NCT01276717	University of Rochester\|Massey Cancer Center	Lymphoma	January 2011	Phase 1
NCT02395627	University of California, San Francisco\|Avon Foundation\|Merck Sharp & Dohme LLC	Breast Neoplasms	May 4, 2015	Phase 2
NCT01483690	Therapeutic Advances in Childhood Leukemia Consortium	Acute Lymphoblastic Leukemia\|Precursor B-Cell Lymphoblastic Leukemia\|Precursor T-Cell Lymphoblastic Leukemia	December 2011	Phase 1\|Phase 2
NCT01365065	Bayside Health\|Merck Sharp & Dohme LLC	HIV Positive	May 2011	Phase 2
NCT02419755	St. Jude Children´s Research Hospital	Mixed Lineage Acute Leukemia\|Acute Myeloid Leukemia\|Acute Lymphoid Leukemia	April 14, 2015	Phase 2
NCT00632931	Merck Sharp & Dohme LLC	Advanced Cancer Relapsed\|Advanced Cancer Refractory	July 2007	Phase 1
NCT01075113	Virginia Commonwealth University\|Massey Cancer Center	Liver Cancer	August 10, 2010	Phase 1
NCT01879085	Melissa Burgess, MD\|Merck Sharp & Dohme LLC\|University of Pittsburgh	Sarcoma	September 24, 2013	Phase 1\|Phase 2
NCT00785798	Yale University\|Merck Sharp & Dohme LLC	Relapsed Lymphomas\|Refractory Lymphomas	January 2009	Phase 1\|Phase 2
NCT00127127	Merck Sharp & Dohme LLC	Tumors	June 10, 2005	Phase 1
NCT01728805	Kyowa Kirin, Inc.	Cutaneous T-Cell Lymphoma	November 2012	Phase 3
NCT00324870	National Cancer Institute (NCI)	Clear Cell Renal Cell Carcinoma\|Recurrent Renal Cell Cancer\|Stage III Renal Cell Cancer\|Stage IV Renal Cell Cancer	February 2006	Phase 1\|Phase 2
NCT00635791	University of Colorado, Denver\|Merck Sharp & Dohme LLC\|Bayer	Malignant Solid Tumour\|Renal Cell Carcinoma\|Non Small Cell Lung Carcinoma	March 2008	Phase 1
NCT01000155	Dana-Farber Cancer Institute\|Brigham and Women´s Hospital\|Boston Children´s Hospital\|Merck Sharp & Dohme LLC	Sickle Cell Disease\|Sickle Cell Anemia	October 2009	Phase 2
NCT00735826	Dartmouth-Hitchcock Medical Center\|Merck Sharp & Dohme LLC	Aerodigestive Tract Cancer\|Lung Cancer\|Esophageal Cancer\|Head and Neck Cancer	March 2009	Not Applicable
NCT00875056	Merck Sharp & Dohme LLC	Lymphoma	April 15, 2009	Phase 2
NCT00771472	Merck Sharp & Dohme LLC	Lymphoma	August 2008	Phase 1
NCT00336063	National Cancer Institute (NCI)	Adult Nasal Type Extranodal NK+T-Cell Lymphoma\|Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma\|Recurrent Nasopharyngeal Undifferentiated Carcinoma\|Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7\|Stage IV Nasopharyngeal Undifferentiated Carcinoma AJCC v7	March 3, 2006	Phase 1
NCT00479232	Merck Sharp & Dohme LLC	Leukemia, Myelocytic, Acute Myelodysplastic Syndromes\|Myelodysplastic Syndromes	June 2007	Phase 1
NCT04339751	National Institute of Neurological Disorders and Stroke (NINDS)\|National Institutes of Health Clinical Center (CC)	Cushing´s Disease	November 28, 2022	Phase 2
NCT00503971	Spanish Lung Cancer Group\|Merck Sharp & Dohme LLC	Non-small Cell Lung Cancer	December 2007	Phase 1\|Phase 2
NCT00691210	Columbia University\|Merck Sharp & Dohme LLC	Hodgkin´s Disease\|Non-Hodgkin´s Lymphoma	June 2008	Phase 1
NCT04190056	University of California, San Francisco\|Merck Sharp & Dohme LLC	Anatomic Stage IV Breast Cancer AJCC v8\|Prognostic Stage IV Breast Cancer AJCC v8	March 11, 2021	Phase 2
NCT00537121	Roswell Park Cancer Institute\|Merck Sharp & Dohme LLC	Esophageal Cancer\|Gastric Cancer\|Liver Cancer	November 2006	Phase 1
NCT02349867	Virginia Commonwealth University\|National Cancer Institute (NCI)	Pancreatic Adenocarcinoma\|Stage IA Pancreatic Cancer\|Stage IB Pancreatic Cancer\|Stage IIA Pancreatic Cancer\|Stage IIB Pancreatic Cancer\|Stage III Pancreatic Cancer\|Recurrent Pancreatic Carcinoma	January 29, 2015	Phase 1
NCT05608369	Kyunghee Burkitt, DO, PhD\|Case Comprehensive Cancer Center	HPV-Related Squamous Cell Carcinoma\|Squamous Cell Carcinoma of the Oral Cavity\|Squamous Cell Carcinoma of the Larynx\|Squamous Cell Carcinoma of the Oropharynx\|Squamous Cell Carcinoma of the Hypopharynx	December 1, 2022	Phase 2
NCT00258349	National Cancer Institute (NCI)	Breast Cancer\|Male Breast Cancer\|Recurrent Breast Cancer\|Stage IIIB Breast Cancer\|Stage IIIC Breast Cancer\|Stage IV Breast Cancer	August 2006	Phase 1\|Phase 2
NCT00574587	Albert Einstein College of Medicine\|Merck Sharp & Dohme LLC	Breast Cancer	December 2007	Phase 1\|Phase 2
NCT00227513	National Cancer Institute (NCI)	Unspecified Adult Solid Tumor, Protocol Specific	July 2005	Phase 1
NCT02420613	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Diffuse Intrinsic Pontine Glioma	October 5, 2015	Phase 1
NCT00132067	National Cancer Institute (NCI)\|Gynecologic Oncology Group	Primary Peritoneal Cavity Cancer\|Recurrent Ovarian Epithelial Cancer	October 2005	Phase 2
NCT00499811	National Cancer Institute (NCI)	Adult Grade III Lymphomatoid Granulomatosis\|Adult Nasal Type Extranodal NK+T-cell Lymphoma\|Anaplastic Large Cell Lymphoma\|Angioimmunoblastic T-cell Lymphoma\|Cutaneous B-cell Non-Hodgkin Lymphoma\|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue\|Intraocular Lymphoma\|Nodal Marginal Zone B-cell Lymphoma\|Primary Central Nervous System Hodgkin Lymphoma\|Primary Central Nervous System Non-Hodgkin Lymphoma\|Recurrent Adult Burkitt Lymphoma\|Recurrent Adult Diffuse Large Cell Lymphoma\|Recurrent Adult Diffuse Mixed Cell Lymphoma\|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma\|Recurrent Adult Grade III Lymphomatoid Granulomatosis\|Recurrent Adult Hodgkin Lymphoma\|Recurrent Adult Immunoblastic Large Cell Lymphoma\|Recurrent Adult Lymphoblastic Lymphoma\|Recurrent Adult T-cell Leukemia+Lymphoma\|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma\|Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Grade 3 Follicular Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Marginal Zone Lymphoma\|Recurrent Mycosis Fungoides+Sezary Syndrome\|Recurrent Small Lymphocytic Lymphoma\|Small Intestine Lymphoma\|Splenic Marginal Zone Lymphoma\|Stage III Adult Burkitt Lymphoma\|Stage III Adult Diffuse Large Cell Lymphoma\|Stage III Adult Diffuse Mixed Cell Lymphoma\|Stage III Adult Diffuse Small Cleaved Cell Lymphoma\|Stage III Adult Hodgkin Lymphoma\|Stage III Adult Immunoblastic Large Cell Lymphoma\|Stage III Adult Lymphoblastic Lymphoma\|Stage III Adult T-cell Leukemia+Lymphoma\|Stage III Cutaneous T-cell Non-Hodgkin Lymphoma\|Stage III Grade 1 Follicular Lymphoma\|Stage III Grade 2 Follicular Lymphoma\|Stage III Grade 3 Follicular Lymphoma\|Stage III Mantle Cell Lymphoma\|Stage III Marginal Zone Lymphoma\|Stage III Mycosis Fungoides+Sezary Syndrome\|Stage III Small Lymphocytic Lymphoma\|Stage IV Adult Burkitt Lymphoma\|Stage IV Adult Diffuse Large Cell Lymphoma\|Stage IV Adult Diffuse Mixed Cell Lymphoma\|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma\|Stage IV Adult Hodgkin Lymphoma\|Stage IV Adult Immunoblastic Large Cell Lymphoma\|Stage IV Adult Lymphoblastic Lymphoma\|Stage IV Adult T-cell Leukemia+Lymphoma\|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma\|Stage IV Grade 1 Follicular Lymphoma\|Stage IV Grade 2 Follicular Lymphoma\|Stage IV Grade 3 Follicular Lymphoma\|Stage IV Mantle Cell Lymphoma\|Stage IV Marginal Zone Lymphoma\|Stage IV Mycosis Fungoides+Sezary Syndrome\|Stage IV Small Lymphocytic Lymphoma\|Unspecified Adult Solid Tumor, Protocol Specific\|Waldenström Macroglobulinemia	June 2007	Phase 1
NCT00750178	Merck Sharp & Dohme LLC	Cancer, Advanced	November 1, 2004	Phase 1
NCT04220008	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Recurrent Aggressive Non-Hodgkin Lymphoma\|Recurrent B-Cell Non-Hodgkin Lymphoma\|Recurrent Burkitt Lymphoma\|Recurrent Diffuse Large B-Cell Lymphoma\|Recurrent High Grade B-Cell Lymphoma\|Recurrent T-Cell Non-Hodgkin Lymphoma\|Recurrent Transformed B-Cell Non-Hodgkin Lymphoma	June 1, 2023	Phase 2
NCT01169532	Fox Chase Cancer Center\|National Cancer Institute (NCI)	Lymphoma\|Unspecified Adult Solid Tumor, Protocol Specific	October 2010	Phase 1
NCT00278330	National Cancer Institute (NCI)	Blastic Phase Chronic Myelogenous Leukemia\|Recurrent Adult Acute Lymphoblastic Leukemia\|Recurrent Adult Acute Myeloid Leukemia\|Refractory Anemia With Excess Blasts\|Relapsing Chronic Myelogenous Leukemia\|Untreated Adult Acute Lymphoblastic Leukemia\|Untreated Adult Acute Myeloid Leukemia	January 2006	Phase 1
NCT01617226	University of Birmingham\|Leukemia Research Fund\|Celgene\|Merck Sharp & Dohme LLC	Leukemia, Myeloid, Acute	September 2012	Phase 2
NCT01189266	National Cancer Institute (NCI)	Anaplastic Astrocytoma\|Anaplastic Oligoastrocytoma\|Diffuse Intrinsic Pontine Glioma\|Gliosarcoma	August 9, 2010	Phase 1\|Phase 2
NCT01522976	National Cancer Institute (NCI)	Chronic Myelomonocytic Leukemia\|Chronic Myelomonocytic Leukemia-1\|Chronic Myelomonocytic Leukemia-2\|Myelodysplastic Syndrome\|Myelodysplastic Syndrome With Excess Blasts\|Myelodysplastic Syndrome With Excess Blasts-1\|Myelodysplastic Syndrome With Excess Blasts-2	March 1, 2012	Phase 2
NCT00773838	Merck Sharp & Dohme LLC	Relapsed or Refractory Multiple Myeloma	December 1, 2008	Phase 2
NCT01110876	M.D. Anderson Cancer Center\|Merck Sharp & Dohme LLC	Brain Cancer\|Glioblastoma Multiforme	June 2011	Phase 1\|Phase 2
NCT01174199	Roswell Park Cancer Institute\|Merck Sharp & Dohme LLC	Prostate Cancer\|Adenocarcinoma of the Prostate\|Hormone-resistant Prostate Cancer\|Recurrent Prostate Cancer\|Stage IV Prostate Cancer	February 2012	Phase 1
NCT02035137	New Approaches to Neuroblastoma Therapy Consortium	Neuroblastoma	July 2014	Phase 2
NCT00363883	National Cancer Institute (NCI)	Localized Transitional Cell Cancer of the Renal Pelvis and Ureter\|Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter\|Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter\|Regional Transitional Cell Cancer of the Renal Pelvis and Ureter\|Transitional Cell Carcinoma of the Bladder	June 2006	Phase 2
NCT00005634	Memorial Sloan Kettering Cancer Center\|National Cancer Institute (NCI)	Leukemia\|Lymphoma\|Multiple Myeloma and Plasma Cell Neoplasm\|Prostate Cancer\|Small Intestine Cancer\|Unspecified Adult Solid Tumor, Protocol Specific	January 2000	Phase 1
NCT00994500	National Cancer Institute (NCI)	Childhood Burkitt Lymphoma\|Childhood Central Nervous System Choriocarcinoma\|Childhood Central Nervous System Germ Cell Tumor\|Childhood Central Nervous System Germinoma\|Childhood Central Nervous System Mixed Germ Cell Tumor\|Childhood Central Nervous System Teratoma\|Childhood Central Nervous System Yolk Sac Tumor\|Childhood Choroid Plexus Tumor\|Childhood Craniopharyngioma\|Childhood Diffuse Large Cell Lymphoma\|Childhood Immunoblastic Large Cell Lymphoma\|Childhood Medulloepithelioma\|Childhood Meningioma\|Childhood Mixed Glioma\|Childhood Nasal Type Extranodal NK+T-cell Lymphoma\|Childhood Oligodendroglioma\|Recurrent Childhood Anaplastic Large Cell Lymphoma\|Recurrent Childhood Brain Stem Glioma\|Recurrent Childhood Central Nervous System Embryonal Tumor\|Recurrent Childhood Cerebellar Astrocytoma\|Recurrent Childhood Cerebral Astrocytoma\|Recurrent Childhood Ependymoma\|Recurrent Childhood Grade III Lymphomatoid Granulomatosis\|Recurrent Childhood Large Cell Lymphoma\|Recurrent Childhood Lymphoblastic Lymphoma\|Recurrent Childhood Malignant Germ Cell Tumor\|Recurrent Childhood Medulloblastoma\|Recurrent Childhood Pineoblastoma\|Recurrent Childhood Small Noncleaved Cell Lymphoma\|Recurrent Childhood Subependymal Giant Cell Astrocytoma\|Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor\|Recurrent Childhood Visual Pathway and Hypothalamic Glioma\|Recurrent Childhood Visual Pathway Glioma\|Recurrent+Refractory Childhood Hodgkin Lymphoma\|Unspecified Childhood Solid Tumor, Protocol Specific	August 2009	Phase 1
NCT01608139	M.D. Anderson Cancer Center\|Sabinsa Corporation	Advanced Cancers	November 2012	Phase 1
NCT00858234	Merck Sharp & Dohme LLC	Multiple Myeloma	February 13, 2009	Phase 1
NCT00423449	Merck Sharp & Dohme LLC	Non-Small Cell Lung Cancer	March 2007	Phase 1
NCT00667615	Memorial Sloan Kettering Cancer Center\|Merck Sharp & Dohme LLC\|Northwestern University\|NorthShore University HealthSystem\|Weill Medical College of Cornell University	Hodgkin´s Disease\|Lymphoma	April 2008	Phase 1\|Phase 2
NCT01378481	National Cancer Institute (NCI)	Adult Anaplastic Astrocytoma\|Adult Anaplastic Oligodendroglioma\|Adult Giant Cell Glioblastoma\|Adult Glioblastoma\|Adult Gliosarcoma\|Adult Mixed Glioma\|Recurrent Adult Brain Neoplasm	June 2012	Phase 1
NCT00937495	National Cancer Institute (NCI)	Recurrent Adult Soft Tissue Sarcoma\|Stage III Adult Soft Tissue Sarcoma\|Stage IV Adult Soft Tissue Sarcoma	June 2009	Phase 2
NCT02114502	M.D. Anderson Cancer Center	Myeloma	September 2014	Phase 2
NCT03212989	University of North Carolina, Chapel Hill\|National Heart, Lung, and Blood Institute (NHLBI)	HIV-1 Infection	June 27, 2017	Phase 1
NCT01039363	Samsung Medical Center	Acute Myeloid Leukemia		Phase 2
NCT00673153	Fred Hutchinson Cancer Center\|National Cancer Institute (NCI)	Adult Acute Megakaryoblastic Leukemia (M7)\|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)\|Adult Acute Monoblastic Leukemia (M5a)\|Adult Acute Monocytic Leukemia (M5b)\|Adult Acute Myeloblastic Leukemia With Maturation (M2)\|Adult Acute Myeloblastic Leukemia Without Maturation (M1)\|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities\|Adult Acute Myeloid Leukemia With Del(5q)\|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)\|Adult Acute Myelomonocytic Leukemia (M4)\|Adult Erythroleukemia (M6a)\|Adult Pure Erythroid Leukemia (M6b)\|Untreated Adult Acute Myeloid Leukemia	March 2008	Phase 2
NCT00972478	National Cancer Institute (NCI)	Ann Arbor Stage II Non-Hodgkin Lymphoma\|Ann Arbor Stage III Non-Hodgkin Lymphoma\|Ann Arbor Stage IV Non-Hodgkin Lymphoma	November 15, 2010	Phase 1\|Phase 2
NCT01720875	University of Leeds\|Myeloma UK\|Merck Sharp & Dohme LLC	Multiple Myeloma	August 9, 2013	Phase 2
NCT01534260	Hamid Sayar\|Millennium Pharmaceuticals, Inc.\|Bayer\|Merck Sharp & Dohme LLC\|Indiana University	Acute Myeloid Leukemia	February 10, 2012	Phase 1\|Phase 2
NCT01187446	Stanford University	Cutaneous Lymphoma\|Cutaneous T-cell Lymphoma	December 2010	Phase 1\|Phase 2
NCT00601718	University of Washington\|National Cancer Institute (NCI)	Adult Nasal Type Extranodal NK+T-cell Lymphoma\|Anaplastic Large Cell Lymphoma\|Angioimmunoblastic T-cell Lymphoma\|Contiguous Stage II Mantle Cell Lymphoma\|Cutaneous B-cell Non-Hodgkin Lymphoma\|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue\|Nodal Marginal Zone B-cell Lymphoma\|Noncontiguous Stage II Mantle Cell Lymphoma\|Recurrent Adult Burkitt Lymphoma\|Recurrent Adult Diffuse Large Cell Lymphoma\|Recurrent Adult Diffuse Mixed Cell Lymphoma\|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma\|Recurrent Adult Grade III Lymphomatoid Granulomatosis\|Recurrent Adult Hodgkin Lymphoma\|Recurrent Adult Immunoblastic Large Cell Lymphoma\|Recurrent Adult Lymphoblastic Lymphoma\|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma\|Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Grade 3 Follicular Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Marginal Zone Lymphoma\|Recurrent Mycosis Fungoides+Sezary Syndrome\|Recurrent Small Lymphocytic Lymphoma\|Splenic Marginal Zone Lymphoma\|Stage I Cutaneous T-cell Non-Hodgkin Lymphoma\|Stage I Mantle Cell Lymphoma\|Stage I Mycosis Fungoides+Sezary Syndrome\|Stage II Cutaneous T-cell Non-Hodgkin Lymphoma\|Stage II Mycosis Fungoides+Sezary Syndrome\|Stage III Cutaneous T-cell Non-Hodgkin Lymphoma\|Stage III Mantle Cell Lymphoma\|Stage III Mycosis Fungoides+Sezary Syndrome\|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma\|Stage IV Mantle Cell Lymphoma\|Stage IV Mycosis Fungoides+Sezary Syndrome\|Waldenström Macroglobulinemia	December 2007	Phase 1\|Phase 2
NCT00816283	City of Hope Medical Center\|National Cancer Institute (NCI)	Leukemia	September 2008	Phase 1
NCT01421173	M.D. Anderson Cancer Center	Lymphoma	August 2011	Phase 1
NCT00251589	Merck Sharp & Dohme LLC	Carcinoma, Non-Small-Cell Lung	January 2006	Phase 1\|Phase 2
NCT01193842	National Cancer Institute (NCI)	AIDS-Related Plasmablastic Lymphoma\|AIDS-Related Primary Effusion Lymphoma\|Ann Arbor Stage I Diffuse Large B-Cell Lymphoma\|Ann Arbor Stage I Grade 3 Follicular Lymphoma\|Ann Arbor Stage II Diffuse Large B-Cell Lymphoma\|Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma\|Ann Arbor Stage II Grade 3 Non-Contiguous Follicular Lymphoma\|Ann Arbor Stage III Diffuse Large B-Cell Lymphoma\|Ann Arbor Stage III Grade 3 Follicular Lymphoma\|Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma\|Ann Arbor Stage IV Grade 3 Follicular Lymphoma\|HIV Infection\|Plasmablastic Lymphoma\|Primary Effusion Lymphoma\|Recurrent Diffuse Large B-Cell Lymphoma\|Recurrent Grade 3 Follicular Lymphoma	October 6, 2010	Phase 1\|Phase 2
NCT00127140	Merck Sharp & Dohme LLC	Lymphoma	June 2005	Phase 1
NCT00642954	Merck Sharp & Dohme LLC	Relapsed or Refractory Multiple Myeloma	February 13, 2008	Phase 1
NCT00918489	Heidelberg University\|Merck Sharp & Dohme LLC	Soft Tissue Sarcoma	May 2010	Phase 2
NCT04308330	New York Medical College	Ewing Sarcoma\|Rhabdomyosarcoma\|Wilms Tumor\|Neuroblastoma\|Hepatoblastoma\|Germ Cell Tumor	March 17, 2017	Phase 1
NCT01281176	National Cancer Institute (NCI)	Adult Solid Neoplasm	February 9, 2011	Phase 1

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : ≥ 100 mg/mL ( 378.33 mM )

* "≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.7833 mL	18.9165 mL	37.8329 mL
5 mM	0.7567 mL	3.7833 mL	7.5666 mL
10 mM	0.3783 mL	1.8916 mL	3.7833 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 20% HP-β-CD in saline

Solubility: 3.33 mg/mL (12.60 mM); Clear solution; Need ultrasonic
2.

Add each solvent one by one: 5% DMSO >> 40% PEG300 >> 5% Tween-80 >> 50% saline

Solubility: ≥ 2.5 mg/mL (9.46 mM); Clear solution
3.

Add each solvent one by one: 5% DMSO >> 95% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (9.46 mM); Clear solution
4.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.08 mg/mL (7.87 mM); Clear solution
5.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.08 mg/mL (7.87 mM); Clear solution
6.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.08 mg/mL (7.87 mM); Clear solution
7.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.08 mg/mL (7.87 mM); Clear solution
8.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.08 mg/mL (7.87 mM); Clear solution
9.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.08 mg/mL (7.87 mM); Clear solution

* All of the co-solvents are available by MCE.

References

[1] Hrzenjak A et al. Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo. Mol Cancer. 2010 Mar 4;9:49.
[2] Lautz TB, et al. The effect of vorinostat on the development of resistance to NSC 123127 in neuroblastoma. PLoS One. 2012;7(7):e40816.
[3] Richon VM, et al. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):3003-7.
[4] Xu WS, et al. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene. 2007 Aug 13;26(37):5541-52.
[5] Pérez-Cañamás A, et al. Sphingomyelin-induced inhibition of the plasma membrane calcium ATPase causes neurodegeneration in type A Niemann-Pick disease. Mol Psychiatry. 2017 May;22(5):711-723.
[6] Wang J, et al. Snail determines the therapeutic response to mTOR kinase inhibitors by transcriptional repression of 4E-BP1. Nat Commun. 2017 Dec 20;8(1):2207.
[7] Banerjee NS, et al. Vorinostat, a pan-HDAC inhibitor, abrogates productive HPV-18 DNA amplification. Proc Natl Acad Sci U S A. 2018 Nov 20;115(47):E11138-E11147.

Synonyms

Octanediamide, N¹-hydroxy-N⁸-phenyl-

Octanediamide, N-hydroxy-N′-phenyl-

N¹-Hydroxy-N⁸-phenyloctanediamide

SAHA

Suberoylanilide hydroxamic acid

Vorinostat

Zolinza

N-Hydroxy-N′-phenyloctanediamide

Suberoyl anilide bishydroxamide

WT 171

Request a Quote

Please fill in your details below to request a COA for our product. We will send the COA to the provided email address promptly.

Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.

Information

Shipping
Privacy notice
Terms of Service
About us
Contact us

Customer service

Search
Custom Synthesis

My account

My account
Orders
Addresses
Shopping cart